683 Capital Management’s Calidi Biotherapeutics CLDI Stock Holding History

683 Capital Management’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-316	Closed	-$4.32K	–	228
2024 Q3	$4.32K	Hold	316	–	–	﹤0.01%	132
2024 Q2	$7.58K	Sell	316 -84	-21%	-$2.68K	﹤0.01%	131
2024 Q1	$27.1K	Buy	+400	New	+$40.9K	﹤0.01%	112
2023 Q3	–	Sell	-2,500	Closed	-$3.15M	–	159
2023 Q2	$3.15M	Hold	2,500	–	–	0.23%	84
2023 Q1	$3.08M	Hold	2,500	–	–	0.23%	102
2022 Q4	$3.05M	Hold	2,500	–	–	0.26%	87
2022 Q3	$2.96M	Sell	2,500 -7,500	-75%	-$8.99M	0.23%	86
2022 Q2	$11.9M	Hold	10,000	–	–	0.84%	38
2022 Q1	$11.9M	Buy	10,000 +8,333	+500%	+$9.85M	0.64%	42
2021 Q4	$1.96M	Buy	+1,667	New	+$1.96M	0.07%	141

Other funds holding CLDI

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

CPR Investments Rochester, Michigan $130M AUM 29.56% 1-Year Est. Return

DWM

Drive Wealth Management Lehi, Utah $474M AUM 23.44% 1-Year Est. Return

RWI

Red Wave Investments Dillsburg, Pennsylvania $335M AUM 15.13% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCI

RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

683 Capital Management's CLDI Position: Q4 2024 in Review

683 Capital Management sold out of Calidi Biotherapeutics (CLDI) in Q4 2024, closing a stake of 316 shares — an estimated $4.32K sold.

683 Capital Management first reported a position in CLDI in Q4 2021 and held it in 10 quarters. The position peaked at $11.9M in Q2 2022. 33 funds tracked by Wall St. Rank hold CLDI as of Q4 2024.

683 Capital Management reported no remaining Calidi Biotherapeutics position as of Q4 2024 after selling out during the quarter.
683 Capital Management sold 316 Calidi Biotherapeutics shares in Q4 2024, an estimated $4.32K.
683 Capital Management first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 10 quarters.
683 Capital Management's Calidi Biotherapeutics position peaked at $11.9M in Q2 2022.
33 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q4 2024.

Based on 683 Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.